[HTML][HTML] Plasma fibroblast growth factor-21 levels in patients with inborn errors of metabolism
Molecular Genetics and Metabolism Reports, 2017•Elsevier
Abstract Fibroblast growth factor-21 (FGF21) levels are elevated in patients with primary
mitochondrial disorders but have not been studied in patients with inborn errors of
metabolism (IEM) known to have secondary mitochondrial dysfunction. We measured
plasma FGF21 by ELISA in patients with and without IEM. FGF21 levels were higher in
patients with IEM compared to without IEM (370 pg/dL vs. 0–65 pg/dL). Further study of
FGF21 as a biomarker in IEM is warranted.
mitochondrial disorders but have not been studied in patients with inborn errors of
metabolism (IEM) known to have secondary mitochondrial dysfunction. We measured
plasma FGF21 by ELISA in patients with and without IEM. FGF21 levels were higher in
patients with IEM compared to without IEM (370 pg/dL vs. 0–65 pg/dL). Further study of
FGF21 as a biomarker in IEM is warranted.
Abstract
Fibroblast growth factor-21 (FGF21) levels are elevated in patients with primary mitochondrial disorders but have not been studied in patients with inborn errors of metabolism (IEM) known to have secondary mitochondrial dysfunction. We measured plasma FGF21 by ELISA in patients with and without IEM. FGF21 levels were higher in patients with IEM compared to without IEM (370 pg/dL vs. 0–65 pg/dL). Further study of FGF21 as a biomarker in IEM is warranted.
Elsevier